Related Experiment Videos
Intensive combined-modality therapy in small cell lung cancer
N Thatcher1, P Lorrigan, P Burt
1CRC Department of Medical Oncology, Christie Hospital, Manchester, UK.
Seminars in Oncology
|June 1, 1994
Summary
The ifosfamide, carboplatin, and etoposide (ICE) chemotherapy regimen, with or without vincristine (VICE), showed a 2-year survival rate of at least 30% in 166 patients. Further evaluation is underway for growth factor support to manage myelosuppression.
Area of Science:
- Oncology
- Pharmacology
Background:
- Review of ifosfamide/carboplatin/etoposide (ICE) chemotherapy and ICE plus mid-cycle vincristine (VICE).
- Integration of thoracic radiotherapy and prophylactic cranial irradiation in later studies.
- Patient populations characterized by adequate Karnofsky performance status and biochemical screening, without intensive staging.
Purpose of the Study:
- To review the efficacy and outcomes of ICE and VICE chemotherapy regimens.
- To assess survival rates and treatment policies in patients receiving VICE chemotherapy.
- To explore strategies for managing myelosuppression associated with VICE therapy.
Main Methods:
- Review of three consecutive studies involving 166 patients treated with VICE chemotherapy.
- Policy of no dose reduction over six courses of VICE chemotherapy.
- Minimum follow-up duration of 26 months.
Main Results:
- A 2-year survival rate of greater than or equal to 30% was observed.
- No dose reductions were implemented over six courses of VICE chemotherapy.
- Hematopoietic growth factor support is under evaluation to mitigate myelosuppression.
Conclusions:
- The VICE chemotherapy regimen demonstrates a notable survival rate in the studied patient cohort.
- The established treatment protocol without dose reduction over six cycles yielded a survival rate of at least 30%.
- Ongoing research focuses on growth factor support to address significant myelosuppression observed with VICE therapy.